On this basis, the EC50 (50% effective concentration) of
rosiglitazone was calculated as 9.8 mcM.
Rosiglitazone also suppressed replication of HBV strains with core promoter and/or precore mutations in addition to the wild type strain.
"In this study, it was suggested that the replication of HBV was inhibited by rosiglitazone," the researchers concluded. "The mechanism is uncertain and is being investigated now."
12/4/09
References
T Bader, B Korba, and M Bronze.